Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

US Patent 11667722 · Granted Jun 6, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric antigen receptor and CAR-T cells that bind BCMA2025
Chimeric antigen receptor and CAR-T cells that bind BCMA2025
Extracorporeal devices for methods for treating diseases associated with anti-ne2024
Chimeric antigen receptor and CAR-T cells that bind BCMA2024
Chimeric antigen receptor and CAR-T cells that bind BCMA2024
Humanized antibodies against CD269 (BCMA)2023
Humanized antibodies against CD269 (BCMA)2023
Humanized antibodies against CD269 (BCMA)2023
Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use th2023
Gamma-carboline compounds for the detection of Tau aggregates2022
Compounds for imaging Tau protein aggregates2020
Humanized antibodies against CD269 (BCMA)2020